| Ytd | -6.21% | |
| 1y | -49.04% |
| Open | 0.85 | Prev Close | 0.84 | Low | 0.78 | High | 0.85 | Mkt Cap | 10.07M |
| Vol | 475.73K | Avg Vol | 217.11K | EPS | -0.94 | P/E | N/A | Forward P/E | -3.08 |
| Beta | 1.74 | Short Ratio | 0.55 | Inst. Own | 43.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.71 | 200-d Avg | 0.83 | 1yr Est | 15.67 |
APRE News
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Com
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regul
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analy
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stag
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and st
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analy
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred
Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Manag
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results bef
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced ad
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Pati
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and A
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 i
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in end